Physician profile
Varada Divgi
NPI 1134270440
$388.60
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $43.30 · 2022: $104.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $103.68 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $50.61 | 2019-2020 | |
| Glaxosmithkline, LLC. | $43.34 | 2019 | |
| Advanced Respiratory, INC | $38.29 | 2019 | |
| Eisai INC. | $35.00 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $26.66 | 2019-2020 | |
| Philips North America LLC | $24.86 | 2019 | |
| Genentech USA, INC. | $21.27 | 2019 | |
| Electromed, INC. | $16.99 | 2019 | |
| Abbvie INC. | $14.82 | 2019 | |
| Genzyme Corporation | $13.08 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Varada Divgi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.